Evonik Industries : Additional charts, Christian Kullmann

Charts to the statement at the

Annual Shareholders' Meeting in Essen (Germany) on August 31, 2020, 10 a.m.

Christian Kullmann, Chairman of the Executive Board of Evonik Industries AG

Dealing with the coronavirus crisis at Evonik

Health

Delivery capability

Social

Responsibility

2

• High standards of hygiene at our sites
• Comprehensive pandemic plan
• Company-wideteam to ensure availability to deliver
• Timely action to counter bottlenecks
• Supply of desinfectants
• Donation of high-performance polymers for medical-grade protective equipment

Strategy implementation over the last 20 months

New divisional structure from 1 July 2020

Chemical operative segments transferred in four divisions

with clear strategic roles

Further optimization of cost basis

SG&A Program to reduce selling

and administrative expenses -

• 20 m ahead of plan in 2019

3

Desinvestment

Divestment of the cyclical

methacrylates business

in 2019

Acquisitions

PeroxyChem and Porocel

to further strengthen

the quality of our portfolio

Strong operating performance in 2019

Sales		Adjusted EBITDA		Adjusted earnings per share

€ 13,108		€ 2,153		€ 1.94
million		million

4

Segment operating performance in 2019

Nutrition & Care		Resource Efficiency		Performance Materials

4,582			5,685			2,043
	728			1,290			224
	15.9			22.7			11.0
Sales	Adj. EBITDA		Sales	Adj. EBITDA		Sales	Adj. EBITDA
(in € million)	(in € million)/		(in € million)	(in € million)/		(in € million)	(in € million)/
	margin (in %)			margin (in %)			margin (in %)

5

Stable dividend and high dividend yield of over 4 percent

Dividend (in €)

+7 %	1.15 1.15	! Dividend policy aligned to
CAGR		continuity and reliability

! Dividend yield of over 4 % among the best

in the chemical industry

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 20191

1 Proposal including the advance payment

6

Outlook 2020 - earnings between € 1.7 bn and € 2.1 bn expected

• 2,153 m

€ 2.1 bn

€ 1.7 bn

20192020E

7

1st half-year 2020 - largely stable performance of our growth segments

• Operating performance of the first half-year impacted by coronavirus crisis
• Nutrition & Care and Resource Efficiency largely stable
• Performance Materials held back by drop in the oil price
• Sales: € 6,069 m
• Adjusted EBITDA: € 970 m
• Adjusted earnings per share: € 0.73

8

Evonik shares - price performance in 2019 and 2020

Price performance 2019

Evonik: +25% Peers in the chemicals sector1: +29%

MDAX: +28%

29

28

27

26

25

24

23

22

21

Jan 19 Mar 19 May 19 Jul 19 Sep 19 Nov 19

Price performance 2020

Evonik: -9%	Peers in the chemicals sector1: -10%
MDAX: -5%

29

27

25

23

21

19

17

15
Jan 20	Mar 20	May 20	Jul 20

1 Definition of the peers in the chemicals sector: Arkema, BASF, Covestro, Clariant, DSM, Lanxess, Solvay

9